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Introduction: Valvuloarterial impedance (Zva) is a measure of global (combined valvular and arterial) load opposing
left ventricular (LV) ejection in aortic stenosis (AS). The present study identified covariates and tested the prognostic
significance of global LV load in patients with asymptomatic AS.
Methods: 1418 patients with mild-moderate, asymptomatic AS in the Simvastatin Ezetimibe in Aortic Stenosis
(SEAS) study were followed for a mean of 43±14 months during randomized, placebo-controlled treatment with
combined simvastatin 40 mg and ezetimibe 10 mg daily. High global LV load was defined as Zva >5 mm Hg/ml/
m2. The impact of baseline global LV load on rate of major cardiovascular (CV) events, aortic valve events and total
mortality was assessed in Cox regression models reporting hazard ratio (HR) and 95% Confidence Intervals (CI).
Results: High global LV load was found in 18% (n=252) of patients and associated with female gender, higher age,
hypertension, more severe AS and lower ejection fraction (all p<0.05). A total of 476 major CV events, 444 aortic
valve events and 132 deaths occurred during follow-up. In multivariate Cox regression analyses, high global LV load
predicted higher rate of major CV events (HR 1.35 [95% CI 1.08-1.71], P=0.010) and aortic valve events (HR 1.41 [95%
CI 1.12-1.79], P=0.004) independent of hypertension, LV ejection fraction, female gender, age, abnormal LV
geometry and AS severity, but failed to predict mortality.
Conclusion: In asymptomatic AS, assessment of global LV load adds complementary information on prognosis to
that provided by hypertension or established prognosticators like AS severity and LV ejection fraction.
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Patients with aortic stenosis (AS) often have hyperten-
sion, [1-5] which is associated with stiffening of the
arterial tree, vascular atherosclerosis and increased inci-
dence of ischemic cardiovascular (CV) events in AS
[6,7]. The combined valvular and arterial load imposed
on the left ventricle (LV) in AS can be noninvasively
quantified by calculation of the valvulo-arterial imped-
ance (Zva) [3]. High global LV load was associated with
increased mortality in a previous retrospective study of
patients with asymptomatic, moderate-to-severe AS [8].
These findings were confirmed in a prospective study by* Correspondence: ashild.rieck@gmail.com
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demonstrating that higher global LV load predicted
increased risk of developing symptoms, cardiac death
and need for aortic valve replacement, independent of
peak aortic jet velocity, left ventricular systolic longitu-
dinal deformation and left atrial area index [9].
The aim of the present study was to further
characterize the phenotype associated with high global
LV load and prospectively evaluate if high global LV load
predicted increased rate of CV events also in patients
with milder AS beyond the increased risk associated
with concomitant hypertension and other known prog-
nosticators in AS like AS severity and LV ejection frac-
tion [7,10].td. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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Study population
The methods and results of the prospective Simvastatin
Ezetimibe in Aortic Stenosis (SEAS) study which tested
the effect of randomized, double-blind, placebo-controlled
treatment with combined simvastatin and ezetimibe on
AS progression and CV morbidity and mortality in 1873
patients with initially asymptomatic, mild-to-moderate
AS, have been reported [11]. All of the patients gave writ-
ten informed consent, and ethical committees in all of the
participating countries approved the study. The study
demonstrated that lipid-lowering treatment reduced is-
chemic CV events in these patients, but did not reduce
progression of AS or need for aortic valve replacement
[12,13]. The present study population included the 1446
of the total 1873 patients in the SEAS study in whom Zva
could be assessed on the baseline echocardiogram and
who had at least one follow-up echocardiogram before
occurrence of any study endpoint (Figure 1). Hypertension
was defined as history of hypertension reported by the
attending physician or elevated blood pressure at the base-
line clinical visit (systolic blood pressure ≥140 mmHg
and/or diastolic blood pressure ≥ 90 mmHg) [14].
Echocardiographic measurements
Study echocardiograms were recorded at 173 SEAS study
sites following a standardized protocol and sent for expert
interpretation at the SEAS echocardiography core labora-
tory at Haukeland University Hospital. The echocardio-
graphic protocol has been previously published [1,15,16].Figure 1 Flow chart of patient enrolment.All reading was performed using off-line digital worksta-
tions with Image ArenaW (TomTec Imaging Systems
GmbH, Unterschleissheim, Germany) software and proof-
read by a single experienced reader (EG).
Assessment of LV geometry and function
LV structure and systolic function were measured follow-
ing the joined European Association of Echocardiography
and American Society of Echocardiography guidelines
[17]. LV mass was calculated using an autopsy validated
formula [18]. LV hypertrophy was considered present
when LV mass/height2.7 exceeded 46.7 g/m2.7 in females
and 49.2 g/m2.7 in men, respectively [19,20]. Relative wall
thickness was calculated as the LV posterior wall thick-
ness/LV internal radius ratio at end-diastole, and concen-
tric geometry was defined as relative wall thickness >0.43
[21]. Left ventricular ejection fraction was assessed by bi-
plane Simpson’s method and considered low if <50% [22].
Assessment of valvular and arterial disease
Severity of AS was assessed following current guidelines
[10]. Energy loss index was calculated by a validated equa-
tion [23,24]. Global LV load was assessed as valvulo-arterial
impedance (Zva) calculated by the method published in the
paper by Briand et al. taking into account the net mean aor-
tic gradient and thus the phenomenon of pressure recovery:
Zva = (Systolic arterial pressure + Mean net aortic gradient)
/ (Stroke volume/body surface area) [3]. The net mean gra-
dient was calculated as the mean aortic gradient corrected
for actual pressure recovery in the individual patient
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sinotubular junction level of the aorta as 4v2 × 2AVA/Aa[1
– (AVA/Aa)], where v is the mean aortic jet velocity, AVA
is calculated by the continuity equation and Aa is the aortic
area [3]. Stroke volume was calculated by the Doppler
method and indexed for body surface area [27].
SEAS study endpoints
The primary endpoint of the prospective SEAS study was
major CV events, including hospitalization for heart
failure due to progression of AS, death from CV causes,
aortic valve replacement, non-fatal myocardial infarction,
hospitalization for unstable angina, coronary revascular-
ization and non-hemorrhagic stroke [13]. Secondary
endpoints were aortic valve related events (combined
congestive heart failure attributed to progression of AS,
aortic valve replacement, and death from CV causes)
and ischemic CV events (combined death from CV
causes, non-fatal myocardial infarction, hospitalization
for unstable angina, coronary revascularization, and
non-hemorrhagic stroke) analysed separately. Total
mortality was a pre-specified tertiary endpoint. All end-
points were adjudicated by an independent committee
blinded to study treatment.
Statistical analyses
IBM SPSS 20.0 (SPSS, Chicago, IL) software was used
for data management and analysis. The study had a stat-
istical power of 95% to detect a 30% difference in inci-
dence of major CV events, the primary study end-point,
with a significance level of 0.01. Data are expressed as
mean ± standard deviation for continuous variables and as
percentages for categorical variables. High global left ven-
tricular load was defined as Zva > 5.00 mm Hg/ml/m2
[3,9]. Groups were compared by Students t-test or chi
square test as appropriate. Covariates of higher global LV
load were identified in univariate correlations and in
multivariate linear regression analysis.
Kaplan-Meier curves were used to compare cumula-
tive hazard of CV events in groups of patients who had
lower vs. higher global LV load at baseline. Uni- and
multivariate Cox regression analyses were used to assess
the relation of baseline global LV load to major CV
events, aortic valve events, ischemic CV events and total
mortality. In the primary multivariate model, global LV
load, randomized study treatment, hypertension, LV
ejection fraction, female gender, age and abnormal LV
geometry were included as covariates. In further models,
conventional indices of AS severity, like aortic valve
area, mean transaortic gradient and peak aortic jet vel-
ocity, were added as covariates. Results are reported as
hazard ratio (HR) and 95% confidence interval (CI). A
two-tailed p <0.05 was considered statistically significant
both in univariate and multivariate analyses.Results
Characteristics of patients with high global LV load
The main clinical and echocardiographic features of the
study population are shown in Table 1. Patients with high
global LV load (n = 252) included more women, patients
with hypertension, were on average older and had higher
blood pressure, lower systemic arterial compliance, and
more severe AS than patients with normal global LV load
(n = 1166) (Table 1). There were no differences in LV
geometry between the two groups (P=0.65).
In multivariate linear regression analysis higher global
LV load at baseline was independently associated with
hypertension, female gender, higher age, lower LV ejection
fraction and more severe AS (Table 2).
Global LV load and prognosis
During a mean follow-up of 43±14 months, a total of
476 major CV events, 444 aortic valve events (387 of
these were aortic valve replacements), 226 ischemic CV
events and 132 deaths occurred (Table 2). Incidences of
major CV events, aortic valve events and death from all
causes were higher among patients with high global LV
load (Table 3, Figure 2). In univariate Cox regression
analyses, high baseline global LV load predicted a 49%
higher rate of major CV events (95% CI 1.21-1.86%,
P<0.001), a 57% higher rate of aortic valve events (95%
CI 1.26-1.96%, P<0.001) as well as 83% higher rate of
death from all causes (95% CI 1.25-2.69%, P=0.002). No
significant association was found between global LV load
and rate of ischemic CV events (Hazard Ratio 1.23, 95%
CI 0.87-1.69, P=0.219). In multivariate analyses, adjust-
ing for randomized study treatment, hypertension, LV
ejection fraction, female gender, age and abnormal LV
geometry, higher global LV load retained its association
with higher rate of major CV events and aortic valve
events, while the association with total mortality was
attenuated (Table 4, primary model). Adding peak aortic
jet velocity and mean aortic gradient to the models did
not change the results (Table 4, secondary model). For-
cing aortic valve area into this model attenuated the
prognostic information provided by global LV load.
Discussion
Concomitant hypertension is common among patients
with AS, being found in up to 86% of patients in previous
studies [1-5]. As recently demonstrated, hypertension in
asymptomatic mild-to-moderate AS is associated with
reduced arterial compliance, more subclinical atheroscler-
osis and increased incidence of ischemic CV events as well
as a 2-fold higher mortality from all causes [7]. Our study
is the first large prospective analysis of the importance of
evaluating combined LV load from valvular and arterial
disease by use of non-invasive valvulo-arterial impedance
in mild to moderate asymptomatic AS. In particular, the
Table 1 Clinical and echocardiographic characteristics of the total study population and groups of patients with high








Age (yrs) 67±10 67±10 70±9 <0.001
Female gender (%) 39 37 45 0.015
Systolic blood pressure (mmHg) 145±20 146±20 155±21 <0.001
Diastolic blood pressure (mmHg) 83±10 82±10 86±10 <0.001
Body mass index (kg/m2) 26.9±4.3 26.7±4.2 27.4±4.5 0.053
Mean blood pressure (mmHg) 104±11 104±11 109±12 <0.001
Pulse pressure (mmHg) 65±18 64±18 70±19 <0.001
Hypertension (%) 83 81 93 <0.001
Heart rate (bmp) 66±11 65±11 68±12 0.001
Antihypertensive treatment (%) 57 55 60 0.078
Angiotensin Converting Enzyme
Inhibitor (%)
15 15 15 0.933
Angiotensin Receptor Blocker (%) 11 11 10 0.737
Calcium Antagonist (%) 17 16 19 0.213
Beta Blocker (%) 28 27 32 0.126
Alpha Blocker 2 2 4 0.006
LV mass index (g/m2.7) 46.2±14.9 46.0±14.8 45.5±14.0 0.659
LV hypertrophy (%) 37 37 36 <0.001
Relative wall thickness (%) 0.36±0.09 0.36±0.08 0.36±0.10 0.769
Normal LV geometry (%) 57 55 57 0.658
Ejection fraction (%) 66±7 67±6 66±7 0.014
Low ejection fraction (%) 1 1 3 0.064
Mitral regurgitation
Grade 1 (%) 38 39 37 0.567
Grade 2(%) 10 9 13 0.089
Grade 3 (%) 1 1 1 0.418
Aortic regurgitation
Grade 1 (%) 43 43 45 0.550
Grade 2(%) 16 17 13 0.109
Grade 3 (%) 1 1 1 0.604
Aortic annulus (cm) 2.19±0.26 2.24±0.26 1.98±0.20 <0.001
Sinotubular aortic diameter (cm) 2.81±0.44 2.83±0.44 2.73±0.42 <0.001
Ascending aorta diameter (cm) 3.92±0.58 3.93±0.58 3.88±0.54 0.250
Peak aortic jet velocity (m/s) 3.08±0.54 3.07±0.53 3.13±0.56 0.131
Aortic valve area (cm2) 1.27±0.45 1.37±0.45 0.86±0.25 <0.001
Energy loss index 0.90±0.47 0.98±0.47 0.55±0.20 <0.001
Mean transaortic gradient (mmHg) 23±9 22±9 24±9 0.026
Systemic arterial compliance 0.71±0.29 0.83±0.33 0.43±0.10 <0.001
Zva (mm Hg/ml • m2) 4.13±1.35 3.50±0.80 5.91±0.92 NA
Total cholesterol (mmol/L) 5.73±1.02 5.70±1.03 5.86±0.96 0.024
Serum creatinine (mmol/L) 93±16 93±15 95±17 0.283
Doppler Stroke volume (ml) 85±25 91±24 58±10 <0.001
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Table 1 Clinical and echocardiographic characteristics of the total study population and groups of patients with high
vs. normal global left ventricular load at baseline (Continued)
LV end-diastolic volume, by
biplane Simpson (ml)
76±25 76±25 79±25 0.125
LV end-systolic volume, by
biplane Simpson (ml)
43±22 42±22 47±24 0.022
Cardiac output by Doppler(L/min) 5.5±1.8 5.9±1.7 3.9±1.0 0.757
Cardiac index (L/min/m2) 2.9±0.9 3.1±09 2.1±0.5 0.629
LV: left ventricular.
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of patients with high global LV load in milder degrees of
AS, as well as demonstrating the impact of global LV load
in prediction of major CV events beyond that provided by
presence of hypertension and other well established prog-
nosticators in asymptomatic AS like AS severity and LV
ejection fraction [7,10].Predictors of high global LV load
The present results add to previous knowledge by dem-
onstrating that also in milder, asymptomatic AS, high
global LV load is associated with a high risk phenotype
including female gender, older age, concomitant hyper-
tension and reduced LV systolic function, independent
of an association with more severe AS by conventional
measures like peak aortic jet velocity, mean aortic gradi-
ent or aortic valve area. Our finding that older age was
associated with higher global LV load is consistent with
the consequences of vascular aging [28]. Physiological
aging is indeed associated with both increased vascular
and ventricular stiffness [29,30]. The pathophysiological
foundation for this finding is uncertain, but multiple
mechanisms have been proposed, including reduced
endothelial function, modulation of collagen, neurohu-
moral signaling and vascular remodeling [31].
Consistent with previous reports, [5] hypertension was a
frequent finding among SEAS patients, and associated
with reduced arterial compliance and higher global LV
load [7]. The association between higher global LV load
and female gender is in agreement with previous findingsTable 2 Covariates of global left ventricular load at study
baseline in multivariate linear regression analysis
(multiple R2= 0.48, p<0.001)
Beta T P value
Constant 18.78 <0.001
Age (years) 0.04 2.08 0.037
Hypertension 0.157 7.67 <0.001
Female gender 0.10 4.82 <0.001
Ejection fraction (%) −0.05 −2.63 0.009
Aortic valve area (m2) −0.67 −31.76 <0.001by Gatzka et al. showing that the observed increased arter-
ial stiffening in women is independent of posture [32].
The negative association between global LV load and LV
ejection fraction is in line with previous studies reporting
increased global LV load to be associated with reduced LV
systolic function assessed by midwall shortening or longitu-
dinal strain [33-35]. In treated hypertensive patients, lower
LV systolic function has been associated with presence of
subclinical coronary artery disease [28]. Of note, 57% of
hypertensive patients in the present study population were
treated. Our findings suggest that among patients with
milder, asymptomatic AS, the phenotype associated with
increased global LV load is typically that of an elderly,
hypertensive woman with reduced LV systolic function.
Global LV load and prognosis in AS
Confirming our hypothesis, global LV load predicted an
increased rate of major CV events, in particular aortic
valve events, independent of hypertension. As previously
reported from the SEAS study, concomitant hyperten-
sion primarily predicted increased risk of ischemic CV
events and mortality [7]. Of note, high global LV load
predicted a statistically significant 49% increased rate of
major CV events and a 55% increased rate of aortic valve
events independent of other features of the high global
LV load phenotype, including higher age, female gender,
concomitant hypertension, and LV ejection fraction as
well as abnormal LV geometry [10,12]. While the associ-
ation with these well-known prognostic factors explained
the increased mortality attributed to high global LV loadTable 3 Incidences of cardiovascular events in groups of












368(32%) 108 (43%) 0.001
Aortic valve
events
340 (29%) 104 (41%) <0.001
Ischemic CV
events
180 (15%) 46 (18%) 0.268
Total mortality 96 (8%) 36 (14%) 0.003
CV: Cardiovascular.












































































































252 240 194 125 9 0
1166 1111 965 683 36 1
252 243 221 173 11 0
1166 1130 1053 826 49 1
252 247 235 193 12 0
1166 1157 1126 928 56 1
252 243 200 128 9 0
1166 1125 989 706 137 1
Figure 2 Impact of high vs. normal global left ventricular load (Zva) on cumulative hazard of major cardiovascular events (Panel A),
aortic valve events (Panel B), ischemic cardiovascular events (Panel C) and total mortality (Panel D) in Kaplan Meier plots.
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different measures of AS severity, higher global LV load
independently predicted a 35% higher rate of major CV
events and a 41% increased rate of aortic valve events.
These findings suggest that global LV load bringscomplementary prognostic information in patients with
mild to moderate asymptomatic AS without otherwise
known CV disease or diabetes.
Our findings expand observations from a retrospective
study by Hachicha et al. in 544 patients with asymptomatic
Table 4 Impact of high global left ventricular load on
patient outcome in multivariate Cox regression analyses
Primary model Secondary
model §
HR (95% CI) ‡ P HR (95% CI) § P
Major CV events 1.49 (1.19-1.86) <0.001 1.35 (1.08-1.69) 0.010
Aortic valve
events
1.55 (1.23-1.95) <0.001 1.41(1.12-1.78) 0.004
Ischemic CV
events
0.99 (0.71-1.39) 0.962 0.91 (0.65-1.28) 0.589
Total Mortality 1.36 (0.91-2.02) 0.138 1.29 (0.86-1.95) 0.215
CV: cardiovascular.
‡Primary model included: Zva, randomized study treatment, hypertension, LV
ejection fraction, female gender, age and abnormal LV geometry.
§ Secondary model included: all covariates in the primary model as well as
peak aortic jet velocity and mean aortic gradient.
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> 3.5 mmHg/ml/m2 predicted increased 4-year mortality,
while the present study defined high global LV load as val-
vuloarterial impedance >5.00 mmHg/ml/m2. Of note, the
present results add to the finding by Lancellotti et al. from
a prospective study in 163 patients with asymptomatic,
moderate to severe AS, that higher global LV load predict
rate of major CV events independent of peak aortic jet vel-
ocity, while longitudinal deformation and left atrial area
index were not assessed in the present study [9]. Further-
more, our findings expand the results from a small study by
Zito et al. in 52 patients with severe asymptomatic AS and
normal LV ejection fraction reporting that combined
increased global LV load and reduced global longitudinal
speckle strain were the best predictors of combined devel-
opment of symptoms, aortic valve replacement and death
[35]. In contrast, no improvement in risk prediction by glo-
bal LV load was demonstrated in a multicentre study by
Levy et al. in patients with low ejection fraction, low gradi-
ent severe, symptomatic AS [36,37].
Study limitations
It has been suggested that calculating global LV load
using central systolic blood pressure might yield better
prediction of adverse outcome. Central blood pressure
was not recorded in the SEAS trial. However, the use of
central instead of brachial aortic blood pressure did not
increment the predictive ability of global LV load in a
recent publication [33].
The present study was not designed to assess the effect
of different types of medication on the progression of
global LV load. 68% of hypertensive SEAS patients were
on blood pressure-lowering medication. However, at
baseline, no difference in use of different classes of anti-
hypertensive agents was found between patients with
lower vs. higher global LV load. Although the study had
high power to detect a difference in incidence of major
CV events, including total mortality, the study did nothave statistical power to detect the observed 20% differ-
ence in ischemic CV event incidence between the
groups. Thus, a type 2 error cannot be excluded for the
lack of association between high global LV load and rate
of ischemic CV events in the present study.
Abbreviations
AS: Aortic valve stenosis; CV: Cardiovascular; LV: Left ventricle;
SEAS: Simvastatin and Ezetimibe in Aortic Stenosis; Zva: Valvulo-arterial
impedance; CI: Confidence Interval.
Competing interests
The authors declare that they have no competing interests.
Authors’ contributions
ÅER, EG and DC designed the study, participated in data collection,
performed the statistical analysis and drafted the manuscript. EB participated
in the data collection. EB MTL CGB GC and SR participated in revisions of the
manuscript. All authors read and approved the final manuscript.
Author details
1Institute of Medicine, University of Bergen, Bergen, Norway. 2Haukeland
University Hospital, Bergen, Norway. 3Asklepios Clinic St. Georg, Department
of Cardiology, Hamburg, Germany. 4Department of Cardiology, Villa Bianca
Hospital, Trento, Italy. 5Herz-Zentrum Bad Krozingen, Bad Krozingen,
Germany. 6Department of Cardiology, North West Heart Centre, University
Hospitals of South Manchester, Manchester, UK.
Received: 29 June 2012 Accepted: 22 October 2012
Published: 5 November 2012
References
1. Rieck AE, Cramariuc D, Staal EM, Rossebo AB, Wachtell K, Gerdts E: Impact
of hypertension on left ventricular structure in patients with
asymptomatic aortic valve stenosis (a SEAS substudy). J Hypertens 2010,
28:377–383.
2. Masuda C, Dohi K, Sakurai Y, Bessho Y, Fukuda H, Fujii S, Sugimoto T,
Tanabe M, Onishi K, Shiraki K, et al: Impact of chronic kidney disease on
the presence and severity of aortic stenosis in patients at high risk for
coronary artery disease. Cardiovasc Ultrasound 2011, 9:31.
3. Briand M, Dumesnil JG, Kadem L, Tongue AG, Rieu R, Garcia D, Pibarot P:
Reduced systemic arterial compliance impacts significantly on left
ventricular afterload and function in aortic stenosis: implications for
diagnosis and treatment. J Am Coll Cardiol 2005, 46:291–298.
4. Herrmann S, Stork S, Niemann M, Lange V, Strotmann JM, Frantz S, Beer M,
Gattenlohner S, Voelker W, Ertl G, Weidemann F: Low-gradient aortic valve
stenosis myocardial fibrosis and its influence on function and outcome. J
Am Coll Cardiol 2011, 58:402–412.
5. Linhartova K, Filipovsky J, Cerbak R, Sterbakova G, Hanisova I, Beranek V:
Severe aortic stenosis and its association with hypertension: analysis of
clinical and echocardiographic parameters. Blood Press 2007, 16:122–128.
6. Agmon Y, Khandheria BK, Meissner I, Schwartz GL, Petterson TM, O’Fallon
WM, Gentile F, Whisnant JP, Wiebers DO, Seward JB: Independent
association of high blood pressure and aortic atherosclerosis: A
population-based study. Circulation 2000, 102:2087–2093.
7. Rieck AE, Cramariuc D, Boman K, Gohlke-Barwolf C, Staal EM, Lonnebakken
MT, Rossebo AB, Gerdts E: Hypertension in aortic stenosis: implications for
left ventricular structure and cardiovascular events. Hypertension 2012,
60:90–97.
8. Hachicha Z, Dumesnil JG, Pibarot P: Usefulness of the valvuloarterial
impedance to predict adverse outcome in asymptomatic aortic stenosis.
J Am Coll Cardiol 2009, 54:1003–1011.
9. Lancellotti P, Donal E, Magne J, Moonen M, O’Connor K, Daubert JC, Pierard
LA: Risk stratification in asymptomatic moderate to severe aortic
stenosis: the importance of the valvular, arterial and ventricular
interplay. Heart 2010, 96:1364–1371.
10. Baumgartner H, Hung J, Bermejo J, Chambers JB, Evangelista A, Griffin BP,
Iung B, Otto CM, Pellikka PA, Quinones M: Echocardiographic assessment
of valve stenosis: EAE/ASE recommendations for clinical practice.
JAmSocEchocardiogr 2009, 22:1–23.
Rieck et al. Cardiovascular Ultrasound 2012, 10:43 Page 8 of 8
http://www.cardiovascularultrasound.com/content/10/1/4311. Rossebo AB, Pedersen TR, Allen C, Boman K, Chambers J, Egstrup K, Gerdts
E, Gohlke-Barwolf C, Holme I, Kesaniemi VA, et al: Design and baseline
characteristics of the simvastatin and ezetimibe in aortic stenosis (SEAS)
study. Am J Cardiol 2007, 99:970–973.
12. Gerdts E, Rossebo AB, Pedersen TR, Boman K, Brudi P, Chambers JB, Egstrup
K, Gohlke-Barwolf C, Holme I, Kesaniemi YA, et al: Impact of baseline
severity of aortic valve stenosis on effect of intensive lipid lowering
therapy (from the SEAS study). Am J Cardiol 2010, 106:1634–1639.
13. Rossebo AB, Pedersen TR, Boman K, Brudi P, Chambers JB, Egstrup K, Gerdts
E, Gohlke-Barwolf C, Holme I, Kesaniemi YA, et al: Intensive lipid lowering
with simvastatin and ezetimibe in aortic stenosis. NEnglJMed 2008,
359:1343–1356.
14. Mancia G, Laurent S, Agabiti-Rosei E, Ambrosioni E, Burnier M, Caulfield MJ,
Cifkova R, Clement D, Coca A, Dominiczak A, et al: Reappraisal of European
guidelines on hypertension management: a European Society of
Hypertension Task Force document. J Hypertens 2009, 27:2121–2158.
15. Cramariuc D, Rieck AE, Staal EM, Wachtell K, Eriksen E, Rossebo AB, Gerdts E:
Factors influencing left ventricular structure and stress-corrected systolic
function in men and women with asymptomatic aortic valve stenosis (a
SEAS Substudy). Am J Cardiol 2008, 101:510–515.
16. Lund BP, Gohlke-Barwolf C, Cramariuc D, Rossebo AB, Rieck AE, Gerdts E:
Effect of obesity on left ventricular mass and systolic function in patients
with asymptomatic aortic stenosis (a Simvastatin Ezetimibe in Aortic
Stenosis [SEAS] substudy). Am J Cardiol 2010, 105:1456–1460.
17. Lang RM, Bierig M, Devereux RB, Flachskampf FA, Foster E, Pellikka PA,
Picard MH, Roman MJ, Seward J, Shanewise J, et al: Recommendations for
chamber quantification. Eur J Echocardiogr 2006, 7:79–108.
18. Devereux RB, Alonso DR, Lutas EM, Gottlieb GJ, Campo E, Sachs I, Reichek N:
Echocardiographic assessment of left ventricular hypertrophy:
comparison to necropsy findings. Am J Cardiol 1986, 57:450–458.
19. De Simone G, Daniels SR, Devereux RB, Meyer RA, Roman MJ, De DO,
Alderman MH: Left ventricular mass and body size in normotensive
children and adults: assessment of allometric relations and impact of
overweight. J Am Coll Cardiol 1992, 20:1251–1260.
20. de Simone G, Devereux RB, Daniels SR, Koren MJ, Meyer RA, Laragh JH:
Effect of growth on variability of left ventricular mass: assessment of
allometric signals in adults and children and their capacity to predict
cardiovascular risk. J Am Coll Cardiol 1995, 25:1056–1062.
21. Roman MJ, Pickering TG, Schwartz JE, Pini R, Devereux RB: Relation of
arterial structure and function to left ventricular geometric patterns in
hypertensive adults. J Am Coll Cardiol 1996, 28:751–756.
22. Lang RM, Bierig M, Devereux RB, Flachskampf FA, Foster E, Pellikka PA,
Picard MH, Roman MJ, Seward J, Shanewise JS, et al: Recommendations for
chamber quantification: a report from the American Society of
Echocardiography’s Guidelines and Standards Committee and the
Chamber Quantification Writing Group, developed in conjunction with
the European Association of Echocardiography, a branch of the
European Society of Cardiology. JAmSocEchocardiogr 2005, 18:1440–1463.
23. Garcia DPP, Dumesnil J, Sakr F, Durand LG: Assessment of aortic valve
stenosis severity: a new Index based on the Energy Loss Concept.
Circulation 2000, 101:765–771.
24. Baumgartner HST, Niederberger J, Schima H, Maurer G: Overestimation“ of
catheter gradients by Doppler ultrasound in patients with aortic
stenosis: a predictable manifestation of pressure recovery. J Am Coll
Cardiol 999, 33:1655–1661.
25. Bahlmann E, Cramariuc D, Gerdts E, Gohlke-Baerwolf C, Nienaber CA, Eriksen
E, Wachtell K, Chambers J, Kuck KH, Ray S: Impact of pressure recovery on
echocardiographic assessment of asymptomatic aortic stenosis: a SEAS
substudy. JACC Cardiovasc Imaging 2010, 3:555–562.
26. Bahlmann E, Nienaber CA, Cramariuc D, Gohlke-Baerwolf C, Ray S, Devereux
RB, Wachtell K, Kuck KH, Davidsen E, Gerdts E: Aortic root geometry in
aortic stenosis patients (a SEAS substudy). Eur J Echocardiogr 2011,
12:585–590.
27. Ihlen H, Endresen K, Myreng Y, Myhre E: Reproducibility of cardiac stroke
volume estimated by Doppler echocardiography. Am J Cardiol 1987,
59:975–978.
28. Gerdts E, Franklin S, Rieck A, Papademetriou V, Wachtell K, Nieminen M,
Dahlof B, Devereux RB: Pulse pressure, left ventricular function and
cardiovascular events during antihypertensive treatment (the LIFE
study). Blood Press 2009, 18:180–186.29. Mitchell GF, Parise H, Benjamin EJ, Larson MG, Keyes MJ, Vita JA, Vasan RS,
Levy D: Changes in arterial stiffness and wave reflection with advancing
age in healthy men and women: the Framingham Heart Study.
Hypertension 2004, 43:1239–1245.
30. Redfield MM, Jacobsen SJ, Borlaug BA, Rodeheffer RJ, Kass DA: Age- and
gender-related ventricular-vascular stiffening: a community-based study.
Circulation 2005, 112:2254–2262.
31. Safar ME, Levy BI, Struijker-Boudier H: Current perspectives on arterial
stiffness and pulse pressure in hypertension and cardiovascular diseases.
Circulation 2003, 107:2864–2869.
32. Gatzka CD, Kingwell BA, Cameron JD, Berry KL, Liang YL, Dewar EM, Reid
CM, Jennings GL, Dart AM: Gender differences in the timing of arterial
wave reflection beyond differences in body height. J Hypertens 2001,
19:2197–2203.
33. Marechaux S, Carpentier E, Six-Carpentier M, Asseman P, LeJemtel TH, Jude
B, Pibarot P, Ennezat PV: Impact of valvuloarterial impedance on left
ventricular longitudinal deformation in patients with aortic valve
stenosis and preserved ejection fraction. Arch Cardiovasc Dis 2010,
103:227–235.
34. Cramariuc D, Cioffi G, Rieck AE, Devereux RB, Staal EM, Ray S, Wachtell K,
Gerdts E: Low-flow aortic stenosis in asymptomatic patients: valvular-
arterial impedance and systolic function from the SEAS Substudy. JACC
Cardiovasc Imaging 2009, 2:390–399.
35. Zito C, Salvia J, Cusma-Piccione M, Antonini-Canterin F, Lentini S, Oreto G,
Di Bella G, Montericcio V, Carerj S: Prognostic significance of
valvuloarterial impedance and left ventricular longitudinal function in
asymptomatic severe aortic stenosis involving three-cuspid valves. Am J
Cardiol 2011, 108:1463–1469.
36. Levy F, Luc Monin J, Rusinaru D, Petit-Eisenmann H, Lelguen C, Chauvel C,
Adams C, Metz D, Leleu F, Gueret P, Tribouilloy C: Valvuloarterial
impedance does not improve risk stratification in low-ejection fraction,
low-gradient aortic stenosis: results from a multicentre study. Eur J
Echocardiogr 2011, 12:358–363.
37. Lancellotti P, Magne J: Valvuloarterial impedance in aortic stenosis: look
at the load, but do not forget the flow. Eur J Echocardiogr 2011,
12:354–357.
doi:10.1186/1476-7120-10-43
Cite this article as: Rieck et al.: Global left ventricular load in
asymptomatic aortic stenosis: covariates and prognostic implication
(the SEAS trial). Cardiovascular Ultrasound 2012 10:43.Submit your next manuscript to BioMed Central
and take full advantage of: 
• Convenient online submission
• Thorough peer review
• No space constraints or color figure charges
• Immediate publication on acceptance
• Inclusion in PubMed, CAS, Scopus and Google Scholar
• Research which is freely available for redistribution
Submit your manuscript at 
www.biomedcentral.com/submit
